Oncology

Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases such as NSCLC and oral premalignant lesions.

A prospective evaluation shows that using large language models within an oncology-specific knowledge graph may help close oncology's enrollment crisis.

Integrative analysis reveals that targeting uPAR with CAR T cells produces durable regressions as well as systemic metastasis clearance.

Data demonstrate that reprogramming immunosuppressive macrophages can convert cold tumors into self-sustaining immune battlefields without lymphodepletion.

Three experts in surgery, radiation, and integrative care disclosed the most salient advances and keen insights in their respective fields.

ONCOLOGY has identified FDA approvals that have affected the oncology treatment paradigm over the last 40 years.

Today the patient-physician relationship that Pergament et al outlined in 1999 is even more prevalent, driven by the rapid development, use, and uptake of social media across all oncology fronts.

Investigators highlighted that emotional and cognitive consequences of beliefs were primarily negative among caregivers of children with cancer.

Yan Leyfman, MD, reflected on resilience and hope in the face of cancer, recounting a 37-year-old diagnosed with stage IV colorectal cancer followed by HIV.

Jesse Fann, MD, MPH, provided insights on the SCOPE trial, which evaluated technology-enhanced collaborative care for depression in patients undergoing active cancer treatment.

Specialized LLMs, AI-assisted CT scans for early detection, and foundational models democratizing pathology are among emerging technologies in oncology care.

COVID-19 and HIV reshaped cancer care, leading to delayed screenings, a surge in telehealth, mental health strain, and equity lessons, many of which clinicians still confront.

In the first-cycle of chemotherapy, patients under 40 were more likely to have higher rates of nausea/vomiting.

Historically, 30% to 60% of AYA patients with cancer experience sexual dysfunction.

Erin Baurle, PsyD, discussed sleep-wake disturbances in patients with cancer and the efficacy of a CBT-I pilot program.

Persistent training and workflow gaps were listed as potential barriers of AYA care among oncologists.

In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

Over the past 40 years, oncology shifted to precision care, smarter toxicity management, AI-guided guidelines, and equity, according to Julie Gralow, MD.

As the journal ONCOLOGY reaches it's 40-year anniversary, it's important to reflect on the transformation of cancer care in that time, according to Julie M. Vose, MD, MBA, and Neil M. Iyengar, MD.

Zolucatetide yielded a DCR of 100% and ORR of 80% among patients with secretase-naive and secretase-treated desmoid tumors.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

This section aims to enhance provider empathy, mitigate burnout, and center the patient’s lived experience within the rigorous framework of medical science.